IL-33 antagonism does not improve chronic atopic dermatitis: What can we learn?

J Allergy Clin Immunol. 2022 Dec;150(6):1410-1411. doi: 10.1016/j.jaci.2022.10.009. Epub 2022 Oct 18.

Authors

Charles F Schuler 4th¹, Johann E Gudjonsson²

Affiliations

¹ Division of Allergy and Clinical Immunology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Mich; Mary H. Weiser Food Allergy Center, Michigan Medicine, University of Michigan, Ann Arbor, Mich.
² Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor, Mich. Electronic address: johanng@med.umich.edu.

No abstract available

Keywords: Atopic dermatitis; IL-33; ST2; astegolimab.

Publication types

Editorial
Comment

MeSH terms

Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Interleukin-33
Protein Transport

Substances

Interleukin-33

Grants and funding